Real treat at today’s lab meeting. Superstar Asst Prof Alessandra Ciullo @AleCiulloPhD presented her innovative work on #exomer therapy (one of our novel #ncRNA drugs) for #Freidreich’s #ataxia, a triplet repeat genetic disorder affecting both the #cerebellum (causing shakes and postural instability) and the heart (lethal #cardiomyopathy). First demonstration of exomer efficacy in a #mitochondrial disease! 👍👏
Eduardo Marban, MD, PhD
Verified account This account is verified. Learn more@MarbanLab
Dr. Eduardo Marban | Executive Director, Smidt Heart Institute @CedarsSinai Views are my own, not institutional policy!
381 Following 2K Followers 1.4K Posts
Latest posts 5
Rigorous studies of deramiocel’s efficacy in @Duchenne @cardiomyopathy. Strong evidence of disease-modifying bioactivity in advanced @DMD, especially in the prespecified subgroup of HOPE-3 subjects with cardiomyopathy at baseline. Progression totally halted over one year of follow-up, with a trend towards net improvement— contrary to the relentless progression of dysfunction and scar in the placebo group. Congrats Jon Soslow, Chet Vila and team!
This weekend at the American Heart Association Scientific Sessions 2026, Dr. Jonathan Soslow of Vanderbilt received the Outstanding Research Award in Pediatric Cardiology for his presentation of the HOPE-3 cardiac results for Deramiocel in Duchenne muscular dystrophy. Congratulations, Dr. Soslow, and thank you to the patients, families and investigators who made this research possible.View quoted post on X
Read the press release: bit.ly/4BMIYM5
#AHA26 #Duchenne #DMD #ScientificSessions26 #Deramiocel $CAPR
This week's lab meeting featured @junlangli discussing his pioneering work on a new #exomer derived from #iPSC extracellular vesicles. Terrific discussion about mechanism and clinical implications!
.@FDA has proclaimed their innovative, proactive approach to rare diseases, but will they deliver? By any measure, #deramiocel exceeds the typical burden of evidence for efficacy and safety in a rare disease, with no less than 5 positive clinical trials. But FDA has yet to approve this novel cell therapy for #Duchenne muscular dystrophy. Meanwhile, boys and young men with advanced #DMD—precisely those who stand to benefit most from deramiocel—are awaiting this potentially transformational therapy. It’s time for FDA to do more than talk about rare diseases! The 28 authors of our recent @TheLancet HOPE-3 paper wrote the attached letter making these points to @FDA-- have a look!
Link for full letter lnkd.in/p/gptcbDKX
Link for full letter lnkd.in/p/gptcbDKX
🙏 Junlang for the opportunity to highlight your work on a new #exomer!
Really enjoyed @MarbanLab's talk yesterday! Always inspiring to hear him bring our work together and put it into a bigger picture! Especially when you get to see your own data on the big screen! 😎🫀 #exomerView quoted post on X